Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Antibe Therapeutics Inc. (T:ATE)

Business Focus: Bio Therapeutic Drugs

Feb 14, 2024 07:00 am ET
Antibe Reports Q3 2024 Interim Financial and Operating Results
“The results of November’s successful PK/PD study have empowered us to make considerable enhancements to the Phase II trial,” commented Dan Legault, Antibe’s CEO. “These upgrades may enable it to qualify as pivotal, potentially unlocking value by simplifying and shortening otenaproxesul’s remaining path to approval. Even with these enhancements, the trial remains on track to initiate next month – we’re looking forward to an exciting year.”
Feb 01, 2024 07:00 am ET
Antibe Extends Early Warrant Exercise Incentive Program
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is extending the Early Warrant Exercise Incentive Program (“Early Warrant Exercise Program”) for its 6.4 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 (“Exercise Price”) and expiring on July 31, 2024 (the “Warrants”).
Dec 29, 2023 07:00 am ET
Antibe Announces Early Warrant Exercise Incentive Program
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce an Early Warrant Exercise Incentive Program (“Early Warrant Exercise Program”) for its 6.5 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 (“Exercise Price”) and expiring on July 31, 2024 (the “Warrants”).
Dec 12, 2023 07:00 am ET
Antibe Therapeutics Announces Amendment to Warrant Terms
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the "Company"), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the “Warrant Extension”), and amending the exercise price (the “Exercise Price Amendment”) of the common share purchase warrants (“Warrants”) of the Company issued on August 13, 2019, June 30, 2020 and February 24, 2021. The amendments will take effect on December 29, 2023.
Nov 13, 2023 07:00 am ET
Antibe Reports Q2 2024 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2023.
Nov 09, 2023 07:00 am ET
Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce the PK results of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation. The study was designed to confirm the drug’s safety and inform the selection of treatment regimens for the upcoming Phase II trial, on track to launch in calendar Q1 2024.
Nov 01, 2023 07:00 am ET
Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce the completion of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study was designed to confirm the drug’s safety and inform treatment regimens for the upcoming Phase II trial, on track to launch in calendar Q1 2024.
Oct 18, 2023 07:00 am ET
Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce the initiation of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study is designed to inform the doses and confirm safety in preparation for the Phase II trial, on track to launch in calendar Q1 2024.
Sep 28, 2023 07:00 am ET
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce Health Canada’s approval to initiate the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial.
Sep 08, 2023 05:00 pm ET
Antibe Announces Results of 2023 Annual Meeting
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the election of directors are provided below:
Aug 21, 2023 03:23 pm ET
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite
TORONTO, Aug. 21, 2023 /CNW/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group.
Aug 14, 2023 07:00 am ET
Antibe Reports Q1 2024 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended June 30, 2023.
Jun 29, 2023 07:30 am ET
Antibe Reports 2023 Year-End Results and Business Highlights
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal year ended March 31, 2023.
Apr 25, 2023 07:00 am ET
Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the Precision in Clinical Trials Summit being held in Boston on May 1 – 2, 2023. Dr. Joseph Stauffer, Antibe’s Chief Medical Officer, will deliver a live presentation discussing Antibe’s clinical program for otenaproxesul:
Apr 18, 2023 07:00 am ET
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference being held in person on April 25-26, 2023. Scott Curtis, Antibe’s Chief Operating Officer, and Dr. Joseph Stauffer, Chief Medical Officer, will deliver the Company’s live presentation:
Apr 11, 2023 07:00 am ET
Antibe Provides April 2023 Corporate Update
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update.
Feb 15, 2023 08:26 am ET
Antibe Reports Q3 2023 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2022.
Feb 15, 2023 07:00 am ET
Antibe Reports Q3 2023 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2022.
Nov 15, 2022 07:00 am ET
Antibe Reports Q2 2023 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2022.
Nov 02, 2022 07:00 am ET
Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to announce the closing of the sale of its Citagenix Inc. subsidiary to HANSAmed Limited (“HANSAmed”), a leading Canadian distributor of pharmaceuticals and medical devices to dental professionals.
Oct 12, 2022 07:00 am ET
Antibe Provides Development Update for Otenaproxesul
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce a major advance in otenaproxesul’s formulation that promises to increase its therapeutic benefit and commercial potential. Accordingly, the Company has filed a patent application that strengthens the drug’s IP protection to 2042.
Sep 09, 2022 05:00 pm ET
Antibe Announces Results of 2022 Annual Meeting
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the election of directors are provided below:
Sep 06, 2022 07:00 am ET
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the selection of a poster presentation of clinical data supporting otenaproxesul’s acute pain efficacy, to be delivered at the PAINWeek National Conference taking place on September 6 - 9 in Las Vegas. The poster will be presented by the lead author of the study and Antibe academic collaborator, James R.W. Glanville, MBChB, MRCP, a UK-based rheumatologist with an academic affiliation to U
Aug 15, 2022 07:00 am ET
Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal quarter ended June 30, 2022.
Jun 30, 2022 07:00 am ET
Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal year ended March 31, 2022.
Jun 15, 2022 07:00 am ET
Antibe Therapeutics Announces Amendment to Warrant Terms
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the "Company"), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the “Warrant Extension”) and amending the exercise price (the “Amended Exercise Price”) of 3,117,957 common share purchase warrants (“Warrants”) of the Company.
May 25, 2022 07:00 am ET
Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors. The Company is also creating two corporate Vice Chair positions to recognize the contributions of Walt Macnee, the outgoing Chair, and Dr. John L. Wallace, Chief Scientific Officer and Director since he founded the Company. As Vice Chairs, they will occupy an esteemed corporate position
May 02, 2022 07:00 am ET
Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the signing of a binding agreement to sell its Citagenix Inc. subsidiary to HANSAmed Limited (“HANSAmed”), a leading Canadian full-service distributor of pharmaceuticals and medical devices to dental professionals.
Apr 25, 2022 07:00 am ET
Antibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, today announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference being held in person on May 2-3, 2022. Dan Legault, Antibe’s CEO, and Dr. Joseph Stauffer, Chief Medical Officer, will deliver the Company’s live presentation:
Feb 14, 2022 07:00 am ET
Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2021.
Nov 16, 2021 07:00 am ET
Antibe Therapeutics Reports Q2 2022 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2021.
Nov 01, 2021 07:00 am ET
Antibe Therapeutics Outlines Plan for Otenaproxesul's Acute Pain Program
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, is pleased to provide further detail on otenaproxesul’s development plan for acute pain indications. Further to its October 14th press release, Antibe has now identified timing for the program’s key regulatory and development milestones for post-operative pain, the Company’s initial acute indication for otenaproxesul.
Oct 14, 2021 07:00 am ET
Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, is pleased to provide an update following a full scientific and strategic review involving external experts and key opinion leaders. The key findings are:
Sep 08, 2021 07:00 am ET
Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13 - 15. Dan Legault, Antibe’s CEO, and Dr. Joseph Stauffer, Chief Medical Officer, will deliver the Company’s pre-recorded presentation:
Aug 19, 2021 05:30 pm ET
Antibe Therapeutics Announces Results of 2021 Annual Meeting
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the election of directors are provided below:
Aug 17, 2021 07:00 am ET
Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has filed its financial and operating results for the fiscal quarter ended June 30, 2021.
Aug 09, 2021 07:00 am ET
Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10 - 12. Dan Legault, Antibe’s CEO, and Dr. Joseph Stauffer, Chief Medical Officer, will deliver the Company’s presentation:
Aug 03, 2021 07:00 am ET
Antibe Therapeutics Provides Clinical Update for Otenaproxesul
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has placed its absorption, metabolism and excretion (“AME”) study of otenaproxesul on a required pause because a pre-specified safety threshold was exceeded. The study is one of several nonclinical and clinical studies being conducted in advance of otenaproxesul’s planned Phase III program.
Jul 27, 2021 07:00 am ET
Jun 28, 2021 07:00 am ET
Antibe Therapeutics Reports 2021 Year-End Financial Results and Business Highlights
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today filed its financial and operating results for the fiscal year ended March 31, 2021.
Jun 25, 2021 07:00 am ET
Antibe Therapeutics Collaborates With Dalriada Drug Discovery to Accelerate Pipeline Expansion
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to target inflammation in a wide range of health conditions, today announced a strategic collaboration with Dalriada Drug Discovery to develop new drug candidates and fortify Antibe’s intellectual property (“IP”) position for its current pipeline.
Jun 07, 2021 07:00 am ET
Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the following U.S.-based virtual investor conferences in June:
Jun 03, 2021 07:00 am ET
Antibe Therapeutics Announces Close of Amalgamation Transaction to Unify Intellectual Property Ownership
Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX:ATE) is pleased to announce that, further to its press release dated May 7, 2021, the Company has completed its previously announced amalgamation transaction (the “Transaction”) to combine Antibe with Antibe Holdings Inc. (“Holdings”). Antibe was founded with an exclusive intellectual property license from Holdings to develop and commercialize the Company’s pipeline drugs. The license obligated the Company to pay royalties to Holdings on revenues derived from this intellectual property. Pursuant to the Transaction, the Company has acqui
May 07, 2021 07:00 am ET
Antibe Therapeutics Announces Agreement to Unify Intellectual Property Ownership
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (“Antibe” or the “Company”), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced that the boards of directors of Antibe and Antibe Holdings Inc. (“Holdings”) have agreed to combine the companies in an amalgamation transaction pursuant to which shareholders of Holdings will receive common shares of the Company in exchange for their shares of Holdings. This agreement follows negotiations originally announced in December 2020.
Apr 14, 2021 07:00 am ET
Antibe Therapeutics to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for inflammation arising from a wide range of medical conditions, is pleased to announce its participation in the Bloom Burton & Co. Healthcare Investor Conference being held virtually on Tuesday, April 20 and Wednesday, April 21. Dan Legault, Antibe’s CEO, will deliver the Company’s presentation and will discuss recent business highlights and its growth strategy:
Mar 29, 2021 07:00 am ET
Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for inflammation arising from a wide range of medical conditions, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for otenaproxesul, in development for the treatment of osteoarthritis pain. This enables Antibe to undertake human clinical trials in the U.S.; as previously announced, Antibe anticipates initiating its Phase III program later this year
Mar 03, 2021 07:00 am ET
Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions, today announced its participation in the following investor conferences in March:
Feb 24, 2021 01:25 pm ET
Antibe Therapeutics Announces Closing of Bought Deal Public Offering
Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX:ATE) today announced that it has closed its previously announced bought deal public offering of 6,727,500 units (the “Offered Securities”) in the capital of the Company at a price of C$6.00 per Offered Security (the “Offering Price”) for aggregate gross proceeds to the Company of C$40,365,000 (the “Offering”), which includes the full exercise of the over-allotment option by the underwriters.
Feb 18, 2021 07:11 am ET
IIROC Trade Resumption - ATE
TORONTO, Feb. 18, 2021 /CNW/ - Trading resumes in:
Feb 17, 2021 03:51 pm ET
IIROC Trading Halt - ATE
TORONTO, Feb. 17, 2021 /CNW/ - The following issues have been halted by IIROC:
Feb 17, 2021 03:39 pm ET
Antibe Therapeutics Announces C$35 Million Bought Deal Public Offering
/NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/
Feb 16, 2021 06:00 am ET
OTC Markets Group Welcomes Antibe Therapeutics Inc. to OTCQX
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has qualified to trade on the OTCQX® Best Market. Antibe Therapeutics Inc. upgraded to OTCQX from the OTCQB® Venture Market.
Feb 12, 2021 07:00 am ET
Antibe Therapeutics Reports Q3 2021 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today filed its financial and operating results for the fiscal quarter ended December 31, 2020.
Feb 09, 2021 07:00 am ET
Antibe Therapeutics Announces Strategic Licensing Deal in China With Nuance Pharma
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) today announced that it has licensed otenaproxesul to Nuance Pharma for commercialization in the Greater China region. Nuance is a biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies to address critical unmet medical needs in China and other Asia Pacific markets. Founded by Mark Lotter, who built the AstraZeneca commercial franchise in China, and led by executives with extensive multinational pharma experience, Nuance focuses on identifying and in-licensing therapies that have achieved be
Feb 08, 2021 10:30 am ET
Antibe Therapeutics Virtually Opens The Market
TORONTO, Feb. 8, 2021 /CNW/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE), and his team joined Dani Lipkin, Director, Global Business Development, TMX Group, to celebrate the company's graduation from TSX Venture Exchange to Toronto Stock Exchange and open the market.
Jan 11, 2021 07:00 am ET
Jan 07, 2021 07:00 am ET
Antibe Therapeutics Strengthens Partnering Advisory Team With Appointment of Don Haut
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Dr. Don Haut to its Partnering Advisory Team.
Dec 18, 2020 07:00 am ET
Antibe Therapeutics Announces Intent to Unify Intellectual Property Ownership
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) (the “Company”), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it has commenced preliminary discussions to amalgamate Antibe Holdings Inc. (“Holdings”) with the Company in order to unify the intellectual property (“IP”) ownership of the Company’s drugs and platform. The Company believes that such an initiative would unlock value for potential partners and investors while simplifying IP protection for pipeline expansion efforts now underway.
Nov 30, 2020 07:00 am ET
Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that, further to a press release issued on November 17, 2020, the consolidation (“Consolidation”) of the Company’s issued and outstanding common shares (“Common Shares”) on the basis of ten (10) pre-consolidation Common Shares for one (1) post-Consolidation Common Share has been approved by the Toronto Stock Exchange (“TSX”). The Consolidation will be effective as of market open tomorrow, December 1, 20
Nov 26, 2020 11:30 am ET
TMX Group, Antibe Therapeutics, C-Suite at The Open
TORONTO, Nov. 26, 2020 /CNW/ - Dan Legault, CEO, Antibe Therapeutics Inc. (TSX: ATE), shares his company's story in an interview with TMX Group.
Nov 24, 2020 07:00 am ET
Antibe Therapeutics Strengthens Governance and U.S. Capital Markets Expertise With Appointment of Two Independent Directors
Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Robert E. Hoffman and Jennifer McNealey to its Board of Directors.
Nov 17, 2020 07:00 am ET
Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing
Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it intends to complete a consolidation of its issued and outstanding common shares (“Common Shares”) on the basis of one (1) new Common Share for every ten (10) Common Shares presently issued and outstanding (“Consolidation”). Completion of the Consolidation remains subject to the approval of the Toronto Stock Exchange (“TSX”) and is expected take effect on or about December 1, 2020.
Nov 13, 2020 07:00 am ET
Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the filing of its financial and operating results for the fiscal quarter ended September 30, 2020. The Company's unaudited fiscal Q2 2021 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Nov 10, 2020 07:00 am ET
Antibe Therapeutics Receives Final Approval to Graduate to the Toronto Stock Exchange
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it has received final approval from the Toronto Stock Exchange (“TSX”) to list its common shares on the TSX.
Oct 30, 2020 07:00 am ET
Antibe Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange (“TSXV”) and list its common shares on the TSX.
Sep 15, 2020 07:00 am ET
Antibe Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that Dan Legault, Antibe’s Chief Executive Officer, will present a corporate overview at the upcoming virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2020 at 9:10 am (Eastern Time).
Aug 31, 2020 05:00 pm ET
LD Micro - 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 31, 2020 07:00 am ET
Antibe Therapeutics to Present at Upcoming Conferences
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences:
Aug 24, 2020 06:00 pm ET
Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The Company's unaudited fiscal Q1 2021 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Aug 20, 2020 05:00 pm ET
Antibe Therapeutics Announces Results of Annual and Special Meeting
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information circular (the “Circular”) were approved, including:
Aug 06, 2020 07:00 am ET
Antibe Therapeutics Engages Stern IR for Investor Relations Services
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support efforts to broaden visibility within the US capital markets.
Aug 05, 2020 09:00 am ET
LD Micro Announces Preliminary List of Presenters for the LD 500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 04, 2020 07:00 am ET
Jul 24, 2020 07:15 pm ET
Antibe Therapeutics Reports 2020 Year-End Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. The Company's audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR.
Jun 30, 2020 09:33 am ET
Antibe Therapeutics Announces Closing of $28.75 Million Bought Deal Offering
Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Antibe Therapeutics Inc. (TSXV: ATE) ("Antibe" or the "Company") announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the "Units") at a price of $0.40 per Unit (the "Offering Price") plus the exercise in full of the Underwriters' over-allotment option of 9,375,000 units for aggregate gross proceeds of $28,750,000 (the "Offering"). The Offering was made pursuant to an underwriting agreement dated June 15, 2020 with a syndicate of underwriters led by Bloom Burton Securities Inc., together with Echelon Wealth Partners Inc., Paradigm Capital Inc., Raymond James Ltd., Stifel GMP and Industrial Alliance Securities Inc. (collectively, the "Underwriters").
Jun 10, 2020 09:11 am ET
IIROC Trading Resumption - ATE
VANCOUVER, BC, June 10, 2020 /CNW/ - Trading resumes in:
Jun 09, 2020 03:55 pm ET
Antibe Therapeutics Announces $25 Million Bought Deal Unit Offering
Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc. and including Echelon Wealth Partners Inc., Paradigm Capital Inc., Raymond James Ltd., Stifel GMP and Industrial Alliance Securities Inc. (the "Underwriters"), pursuant to which the Underwriters have agreed to purchase 62,500,000 units of the Company (the "Units") at a price of $0.40 per Unit for gross proceeds of $25,000,000 (the "Offering"). Each Unit shall consist of one common share of the Compa
Jun 09, 2020 03:07 pm ET
IIROC Trading Halt - ATE
VANCOUVER, BC, June 9, 2020 /CNW/ - The following issues have been halted by IIROC:
Jun 02, 2020 03:58 pm ET
Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) will host a conference call Thursday, June 4 at 10:00 am ET to discuss the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346. Management will provide a brief summary of the results followed by a Q&A session for analysts.
Jun 01, 2020 06:30 am ET
Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met the primary endpoint in the Phase 2B dose-ranging, efficacy study. Both the 250 mg and 200 mg doses of ATB-346 demonstrated superiority to placebo in reducing osteoarthritis (“OA”) pain with a high level of statistical significance. The 150 mg dose of ATB-346, although not powered for statistical significance, demonstrated more potency than expected and the lowest effective dose is still to be established. The drug was safe and well tolerated during this study. The Company is planning a p
May 06, 2020 07:00 am ET
Antibe Therapeutics Announces the Hiring of Chief Medical Officer
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the hiring of Dr. Joseph Stauffer in the new role of Chief Medical Officer (“CMO”). An anesthesiologist, Dr. Stauffer has served as CMO in public and private drug therapy companies for nearly 20 years, building teams of physicians, scientists, regulators and safety experts to drive clinical success for a number of chronic and acute pain assets. Dr. Stauffer will assume a leadership role in Antibe’s clinical development strategy and its increasing engagement with global regulatory agencies and potential large-market partn
May 04, 2020 06:30 am ET
Antibe Therapeutics Updates Timing for Top-Line Results From Completed Phase 2B Dose-Ranging, Efficacy Study
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today provides an update on the timing of top-line results for the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. Involving 360 patients across 40 clinical sites, this study is one of the largest ever undertaken in Canada. The Company is pleased to report that its clinical research organization (“CRO”), Veristat, was able to complete the trial and capture all patient data without compromising the size and integrity of the study. However, ongoing hospital restrictions, clinic closures and complexities arising from remote work
Feb 28, 2020 07:00 am ET
Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-ranging, Efficacy Study of Lead Drug, ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that the last patient has been enrolled and is on treatment in the Phase 2B dose-ranging, efficacy study of Antibe’s lead drug, ATB-346. The study is evaluating the effectiveness of ATB-346 in reducing osteoarthritis (OA) pain compared to placebo in 360 patients.
Feb 25, 2020 07:00 am ET
Antibe Therapeutics Provides Corporate Update and Reports Q3 2020 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended December 31, 2019.
Feb 24, 2020 07:00 am ET
Antibe Therapeutics Announces Research Publication Demonstrating Markedly Enhanced Pain Relief and Increased Safety of Second Pipeline Drug
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the publication of a multi-national study entitled “Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide‐Releasing Anti- Inflammatory Drug (ATB‐352): A Role for Endogenous Cannabinoids”. This article was published in “Antioxidant and Redox Signaling”, a leading international peer-reviewed biomedical journal.
Feb 21, 2020 07:00 am ET
Antibe Therapeutics Recognized as a TSX Venture 50 Company for Second Consecutive Year
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that it has been named a TSX Venture 50™ company for the second consecutive year, in recognition of its performance on the TSX Venture Exchange.
Jan 13, 2020 07:00 am ET
Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the hiring of Dr. Rami Batal in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for our overall drug platform.
Nov 28, 2019 07:00 am ET
Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended September 30, 2019.
Aug 27, 2019 07:45 pm ET
Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, August 27th for the fiscal quarter ended June 30, 2019. The Company’s unaudited fiscal Q1 2020 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Aug 27, 2019 07:00 am ET
Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today provides an update on the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The clinical study commenced in March 2019 and is designed to validate the efficacy of ATB-346 in reducing pain and establish the dose for Phase 3 development. A total of 360 patients with osteoarthritis of the knee are being randomized to either placebo or one of three doses of ATB-346 administered once daily: 150 mg, 200 mg or 250 mg.
Aug 13, 2019 09:06 am ET
Antibe Announces Closing of Public Offering
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that is has closed its previously announced public offering of 26,833,332 units of the Company (the “Units”) at a price of $0.30 per Unit (the “Offering Price”) for aggregate gross proceeds of $8,050,000 (the “Offering”). The Offering was made pursuant to an amended and restated agency agreement effective August 7, 2019 with a syndicate of agents led by Bloom Burton Securities Inc., together with Echelon
Aug 07, 2019 02:39 pm ET
Antibe Therapeutics Announces Filing of Final Short Form Prospectus
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE), a leader in developing safer therapeutics for pain and inflammation, announces that it has filed a final short form prospectus (the “Final Prospectus”) relating to the Company’s marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Final Prospectus, the Offering will be for a minimum of 23,333,333 Units and up to a maximum of 26,833,333 Units for minimum gross proceeds of $7,000,000 and maximum gross proceeds of $8,050,000.
Jul 25, 2019 06:45 pm ET
Antibe Therapeutics Announces Size of Offering
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, announces that its previously-announced marketed offering (the “Offering”) of units of the Company (the “Units”) will consist of 23,333,333 Units for gross proceeds of $7,000,000. In respect of the foregoing, Antibe today filed an amended and restated preliminary short form prospectus (the “Amended and Restated Preliminary Prospectus”), to amend and restate the preliminary short form prospectus dated July 23, 2019.
Jul 24, 2019 09:30 am ET
IIROC Trading Resumption - ATE
VANCOUVER, July 24, 2019 /CNW/ - Trading resumes in:
Jul 23, 2019 04:00 pm ET
Antibe Therapeutics Announces Offering of Units
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has filed a preliminary short form prospectus (the “Preliminary Prospectus”) in connection with a proposed marketed offering of units (the “Units”) of the Company at a price (the “Offering Price”) of $0.30 per Unit (the “Offering”). Each Unit will be comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (each
Jul 23, 2019 03:48 pm ET
IIROC Trading Halt - ATE
VANCOUVER, July 23, 2019 /CNW/ - The following issues have been halted by IIROC:
Jul 16, 2019 09:30 pm ET
Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF) filed its financial and operating results on Tuesday, July 16 for the fourth quarter and the year ended March 31, 2019. The Company's audited 2019 consolidated financial statements, MD&A and AIF are available on SEDAR.
Jul 02, 2019 06:00 pm ET
Antibe Therapeutics Announces Results of Annual General and Special Meeting
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual general and special meeting held earlier today. All resolutions outlined in the management information circular (the “Circular”) were approved, including:
Jun 25, 2019 07:00 am ET
Jun 03, 2019 07:00 am ET
Antibe Therapeutics Unveils Lead Indication for ATB-352, a Potent, Non-Addictive Analgesic for Severe Pain
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the lead indication for its second pipeline drug, ATB-352, a potent and non-addictive analgesic for the treatment of severe pain. The Company will be targeting post-operative pain as the lead indication for ATB-352, a US$9 billion market that is in desperate need of safer and non-addictive therapies.
May 30, 2019 07:00 am ET
Antibe Therapeutics Announces Upcoming Conference Schedule
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce its conference schedule for the upcoming months.
Apr 26, 2019 07:00 am ET
Antibe Therapeutics to Present at 2019 Bloom Burton & Co. Healthcare Investor Conference
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference being held on Tuesday, April 30 - Wednesday, May 1, 2019 in Toronto, Canada.
Apr 16, 2019 07:00 am ET
Phase 2B GI Safety Results For ATB-346 Published in British Journal of Pharmacology
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today highlights that a research article has been published in the British Journal of Pharmacology (“BJP”) on the successful Phase 2B GI safety trial for its lead drug, ATB-346. BJP is considered one of the world’s pre-eminent scientific journals in pharmacology.
Mar 29, 2019 07:00 am ET
Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that its Phase 2B dose-ranging, efficacy study for ATB-346 has formally commenced. Enrollment is open, clinical sites have been activated and patients will now begin screening.
Feb 27, 2019 08:44 am ET
Antibe Therapeutics Inc. Announces Closing of $5.75 Million Bought Deal Offering
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that is has closed its previously announced bought deal public offering of 23,000,000 units of the Company (the “Units”) at a price of $0.25 per Unit (the “Offering Price”) for aggregate gross proceeds of $5,750,000 (the “Offering”), including the exercise in full of the Underwriters’ over-allotment option. The Offering was made pursuant to a
Feb 22, 2019 07:00 am ET
Antibe Therapeutics Recognized as a 2019 TSX Venture 50 Company
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has been named a 2019 TSX Venture 50™ company, an award that recognizes the top performing companies on the TSX Venture Exchange over the past year. Antibe was ranked second in the Clean Technology and Life Sciences sector.
Feb 15, 2019 07:30 pm ET
Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, February 15th for the fiscal quarter ended December 31, 2018. The Company’s unaudited fiscal Q3 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Feb 04, 2019 04:01 pm ET
Antibe Therapeutics Announces $5 Million Bought Deal Offering
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has entered into an agreement with Bloom Burton Securities Inc., on behalf of a syndicate of underwriters including Echelon Wealth Partners Inc. and Dominick Capital Corporation (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 20,000,000 units of the Company (the “Units”) at a price of $0.25 per Unit (the
Feb 04, 2019 03:16 pm ET
IIROC Trading Resumption - ATE
VANCOUVER, Feb. 4, 2019 /CNW/ - Trading resumes in:
Feb 04, 2019 03:01 pm ET
IIROC Trading Halt - ATE
VANCOUVER, Feb. 4, 2019 /CNW/ - The following issues have been halted by IIROC:
Jan 21, 2019 07:00 am ET
Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has received approval from Health Canada to initiate the second part of its Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The primary objective of the study is to evaluate the efficacy of ATB-346 in reducing osteoarthritis (“OA”) pain over a 14-day treatment period. The study will involve a total of 360 patients with OA of the knee, who will be randomized to placebo o
Dec 19, 2018 07:00 am ET
Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has received gross proceeds of $1.6 million from the exercise of warrants. A total of 7,066,001 warrants were exercised at a price of $0.22 with expiries on December 15th and 21st, 2018. Nearly all of the warrants expiring in December 2018 were exercised.
Nov 30, 2018 07:00 am ET
Antibe Therapeutics to Present at the 11th Annual LD Micro Main Event on December 4, 2018
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has been invited to present at the 11th Annual LD Micro Main Event Investor Conference being held December 4-6, 2018 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
Nov 27, 2018 07:00 am ET
Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the successful completion of part one of the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The study was conducted in 24 healthy volunteers who were randomized to once daily doses of ATB-346 at 250 mg, 200 mg or 150 mg.
Nov 23, 2018 06:00 pm ET
Antibe Therapeutics Reports Q2 2019 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, November 23rd for the fiscal quarter ended September 30, 2018. The Company’s unaudited fiscal Q2 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Oct 22, 2018 07:00 am ET
Antibe Therapeutics Establishes Business Development Advisory Board
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has established a strategic advisory board to support its business development activities.
Oct 10, 2018 07:00 am ET
Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has received approval from Health Canada to initiate the first part of its Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The first part of the study is a metabolism protocol that will be conducted in 24 healthy volunteers over a 7 day treatment period. The primary objective of the protocol is to determine the principle metabolites of ATB-346 in humans and characteri
Oct 03, 2018 05:00 pm ET
Antibe Therapeutics Announces Grant of Restricted Share Units
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) announces that it has granted restricted share units (“RSUs”) pursuant to the Company’s RSU plan that was adopted at the most recent annual shareholder’s meeting on June 25, 2018.
Sep 05, 2018 07:00 am ET
Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea
Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has entered into an exclusive licensing agreement with Kwang Dong Pharmaceutical Co., Ltd. ("Kwang Dong") for the development and commercialization of Antibe’s lead drug, ATB-346, in South Korea (the “Region”). Kwang Dong is a major pharmaceutical company in the Region, with net sales in excess of US$600 million and over 500 sales representatives.
Aug 29, 2018 06:45 pm ET
Antibe Therapeutics Reports Q1 2019 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Wednesday, August 29th for the fiscal quarter ended June 30, 2018. The Company’s unaudited fiscal Q1 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Aug 29, 2018 07:30 am ET
Antibe Provides Scientific Report on Its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has prepared a comprehensive report of the recently-completed Phase 2B study for its lead drug, ATB-346. The study was completed in March 2018 and demonstrated unequivocal superiority in gastrointestinal (“GI”) safety compared to naproxen, the most prescribed NSAID in the United States.
Jul 31, 2018 07:00 am ET
Antibe Therapeutics Provides Clinical Development Update on Its Lead Drug
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to provide an update on its clinical development activities for its lead drug, ATB-346.
Jul 06, 2018 07:15 pm ET
Antibe Completes Share Issuance in Connection with Citagenix Credit Facility
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) announces that further to its release of June 29, 2018, it has issued to Bloom Burton Healthcare Lending Trust (“BBHLT”) 578,572 common shares in the capital of Company (“Common Shares”) at a deemed issue price of $0.385 per Common Share. The Common Shares were issued in connection with the entry by Citagenix Inc. (“Citagenix”), a subsidiary of the Company, into a $2.25 million secured revolving credit facility (the “Credit Facility”) provided by BBHLT to replace and
Jul 03, 2018 07:00 am ET
Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the secondary endpoint data from the recent Phase 2B gastrointestinal (“GI”) safety study for its lead drug, ATB-346. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the United States.
Jun 29, 2018 06:37 pm ET
Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, June 29 for the fourth quarter and the year ended March 31, 2018. The Company's audited 2018 consolidated financial statements, MD&A and AIF are available on SEDAR.
Jun 26, 2018 06:00 pm ET
Antibe Therapeutics Announces Results of Annual General and Special Meeting
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual general and special meeting held yesterday. All resolutions proposed to the shareholders were approved, including:
Jun 04, 2018 07:00 am ET
Antibe Therapeutics to Attend 2018 BIO International Convention to Support Partnering Efforts
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, will be attending the 2018 BIO International Convention (“BIO International”) this week in Boston, Massachusetts. BIO International is the largest biopharma partnering event of the year, attracting over 16,000 leaders and business development executives from 5,000 companies across the globe.
May 29, 2018 07:00 am ET
Antibe’s Chief Scientific Officer to Present at 5th World Congress on Hydrogen Sulfide in Biology and Medicine
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its Chief Scientific Officer, John Wallace, will deliver a lecture at the 5th World Congress on Hydrogen Sulfide in Biology and Medicine. The conference is being held at the Intercontinental Yorkville Hotel in Toronto, Canada from May 31st to June 3rd, 2018.
May 24, 2018 07:00 am ET
Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF) is pleased to announce that a team of researchers at the University of Calgary has identified a key mechanism underlying the ability of certain intestinal bacteria to contribute to the ulceration and inflammation that is characteristic of Crohn’s disease and ulcerative colitis (the two forms of IBD). Moreover, they have demonstrated that novel hydrogen sulfide-releasing drugs can reverse these effects, leading to resolution of the inflammation and healing of inte
Apr 30, 2018 07:00 am ET
Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference being held on May 2 – 3, 2018 in Toronto, Canada.
Apr 26, 2018 07:00 am ET
Antibe Therapeutics Announces CEO Letter to Shareholders
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF):
Apr 11, 2018 08:00 pm ET
Antibe Therapeutics Engages Blaise Group International for Executive Search
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) has engaged Blaise Group International (“Blaise Group”), a leading healthcare-focused executive recruitment agency, to augment its global business development expertise. Blaise Group is a leading retained human capital search and strategic services firm exclusively servicing life science organizations on a global basis. In connection with the agreement, Antibe has granted Blaise Group 151,515 options to purchase common shares of the Company that will vest upon the suc
Apr 03, 2018 07:00 am ET
Antibe Therapeutics Provides Financial Update
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation that recently announced a successful Phase 2B clinical trial demonstrating the gastrointestinal safety of its lead drug, reports that the Company now has a significantly augmented balance sheet.
Mar 20, 2018 09:02 am ET
IIROC Trading Resumption - ATE
VANCOUVER, March 20, 2018 /CNW/ - Trading resumes in:
Mar 20, 2018 08:35 am ET
Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal (“GI”) safety study. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the USA. Subjects on ATB-346 exhibited an ulceration rate of 2.5% versus an ulceration rate of 42.1% for subjects o
Mar 19, 2018 02:19 pm ET
IIROC Trading Halt - ATE
VANCOUVER, March 19, 2018 /CNW/ - The following issues have been halted by IIROC:
Mar 13, 2018 10:26 am ET
Antibe Therapeutics Announces No Material Change
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) wishes to advise that it is not aware of any undisclosed material change in the Company’s activities that would account for recent market activity. As previously disclosed in its February 26th, 2018 press release, the Company anticipates being in a position to report top-line results of the Phase 2b clinical trial of its lead drug, ATB-346, during the week of March 19th, 2018.
Feb 27, 2018 09:45 pm ET
Antibe Therapeutics Reports Q3 2018 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, February 27th for the fiscal quarter ended December 31, 2017. The Company’s unaudited fiscal Q3 2018 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Feb 26, 2018 07:00 am ET
Antibe Therapeutics Provides Update on Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) would like to confirm the previously announced timing for its Phase 2B double-blind clinical trial of ATB-346. The final subject has now completed treatment and the subsequent two-week monitoring period. The CRO conducting the study, Topstone Research Inc. (“Topstone”), is currently performing data validation and analysis. Antibe remains on its previously announced schedule and anticipates being in a position to report top-line results during the week of March 19
Jan 29, 2018 07:00 am ET
Antibe Therapeutics Announces Enrollment of Final Subjects in Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine, is pleased to announce that the final subjects have been enrolled and are on treatment in the key Phase 2B double-blind clinical trial of ATB-346. The study is being conducted in 240 healthy volunteers and is designed to demonstrate the unequivocal superiority of ATB-346 in gastrointestinal (“GI”) safety compared to naproxen, the most prescribed nonste
Jan 17, 2018 07:00 am ET
Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietary Name for ATB-346
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE, OTCQB:ATBPF) is pleased to announce that it has engaged Brand Institute, Inc. (“Brand Institute”) to advise on the nonproprietary name for its lead drug candidate, ATB-346.
Nov 28, 2017 10:30 pm ET
Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate Update
Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, November 28th for the fiscal quarter ended September 30, 2017. The Corporation’s unaudited fiscal Q2 2018 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Oct 26, 2017 07:00 am ET
Antibe Therapeutics Announces Key US Distribution Partnership for Its Subsidiary, Citagenix
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its subsidiary, Citagenix Inc. (“Citagenix”), has been selected by Darby Dental Supply, LLC (“Darby Dental”) to be its supplier of premium bone grafting and tissue regeneration products. Darby Dental has been in operation for nearly 70 years and has established itself as one of the largest and most trusted dental distributors in the United States.
Oct 20, 2017 07:00 am ET
Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) will be attending the 2017 CPhI Worldwide conference next week in Frankfurt, Germany. CPhI Worldwide is the world’s largest pharma trade show and considered the leading international pharmaceutical business and networking event. The event will be held on October 24th – 26th and will host over 42,000 pharma industry professionals from over 150 countries.
May 25, 2017 09:49 am ET
IIROC Trading Resumption - ATE
VANCOUVER, May 25, 2017 /CNW/ - Trading resumes in:
May 24, 2017 02:22 pm ET
IIROC Trading Halt - ATE
VANCOUVER, May 24, 2017 /CNW/ - The following issues have been halted by IIROC:
Feb 24, 2017 11:14 am ET
IIROC Trading Resumption - ATE
VANCOUVER, Feb. 24, 2017 /CNW/ - Trading resumes in:
Feb 24, 2017 10:12 am ET
IIROC Trading Halt - ATE
VANCOUVER, Feb. 24, 2017 /CNW/ - The following issues have been halted by IIROC: